New appointments will drive manufacturing efficiency in Sandoz’s generics business and merger and acquisition activities globally.
Ahead of the upcoming loss of exclusivity for biosimilar medicines, Sandoz is restructuring its leadership teams in two key departments: manufacturing and M&A.
On 20 August, Pascal Bouye will succeed Glenn Gerecke as President, Generics Manufacturing & Supply. He will be tasked with driving efficiency and scale in Sandoz’s high-volume generics business.
Bouye has more than three decades of experience in the supply chain sector, chiefly in consumer goods. Previous positions include senior roles at Danone and Mars. These involved leading global teams through complex operational transformations and driving continuous improvement.
In April, Armin Metzger commenced as Sandoz’s President of Biosimilar Development, Manufacturing & Supply, heading up the firm’s new global biosimilar development, manufacturing and supply unit.
Keren Haruvi, President, North America, will also take on responsibility for global M&A activities at Sandoz. She previously held the role of Global Head of M&A at Novartis.
Bouye and Haruvi will assume their new roles on 1 August.
According Sandoz Chief Executive Officer Richard Saynor, the appointments “reflect both the strength of our leadership pipeline and the continued evolution of Sandoz as an independent company. They position us well to capitalise on an unprecedented wave of loss of exclusivity opportunities, our ‘golden decade’, and the significant potential they create to expand patient access to high-quality, affordable medicines.”
[The appointments] position us well to capitalise on an unprecedented wave of loss of exclusivity opportunities, our ‘golden decade’, and the significant potential they create to expand patient access to high-quality, affordable medicines”
Sandoz Chief Executive Officer Richard Saynor
Amid these leadership transitions, in the run up to the biosimilar ‘golden decade’, Sandoz has opened a major biosimilar development centre in Slovenia. The hub supports growth of the firm’s biosimilar pipeline and progression of these medicines efficiently into production.
Additionally, earlier this year Sandoz began a collaboration with Samsung Bioepis through licensing agreement, where it will advance up to five assets, boosting its own biosimilar pipeline by up to 32 assets.
On the regulatory side, US Food and Drug Administration (FDA) in March published draft guidance recommending that PK study can use a non-US-licensed comparator product, if scientifically justified. The agency anticipates this change will reduce biosimilar developer’s PK study costs by up to half, saving approximately $20 million.
No comments yet